vs
Xometry, Inc.（XMTR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Xometry, Inc.的季度营收约是再鼎医药的1.5倍（$192.4M vs $127.1M），Xometry, Inc.同比增速更快（29.5% vs 17.1%），Xometry, Inc.自由现金流更多（$-5.9M vs $-26.7M），过去两年Xometry, Inc.的营收复合增速更高（25.2% vs 20.8%）
Xometry是一家按需制造零部件采购线上平台，服务覆盖原型研发到规模化生产的全流程需求，为各行业客户高效匹配制造产能，简化定制零部件的采购流程，助力企业缩短产品落地周期。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
XMTR vs ZLAB — 直观对比
营收规模更大
XMTR
是对方的1.5倍
$127.1M
营收增速更快
XMTR
高出12.4%
17.1%
自由现金流更多
XMTR
多$20.8M
$-26.7M
两年增速更快
XMTR
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $192.4M | $127.1M |
| 净利润 | $-8.6M | — |
| 毛利率 | 39.1% | 51.0% |
| 营业利润率 | -4.6% | -54.6% |
| 净利率 | -4.5% | — |
| 营收同比 | 29.5% | 17.1% |
| 净利润同比 | 12.7% | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收XMTRZLAB
| Q4 25 | $192.4M | $127.1M | ||
| Q3 25 | $180.7M | $115.4M | ||
| Q2 25 | $162.5M | $109.1M | ||
| Q1 25 | $151.0M | $105.7M | ||
| Q4 24 | $148.5M | $108.5M | ||
| Q3 24 | $141.7M | $101.8M | ||
| Q2 24 | $132.6M | $100.1M | ||
| Q1 24 | $122.7M | $87.1M |
净利润XMTRZLAB
| Q4 25 | $-8.6M | — | ||
| Q3 25 | $-11.6M | $-36.0M | ||
| Q2 25 | $-26.4M | $-40.7M | ||
| Q1 25 | $-15.1M | $-48.4M | ||
| Q4 24 | $-9.9M | — | ||
| Q3 24 | $-10.2M | $-41.7M | ||
| Q2 24 | $-13.7M | $-80.3M | ||
| Q1 24 | $-16.6M | $-53.5M |
毛利率XMTRZLAB
| Q4 25 | 39.1% | 51.0% | ||
| Q3 25 | 39.9% | 59.5% | ||
| Q2 25 | 40.1% | 60.6% | ||
| Q1 25 | 37.3% | 63.6% | ||
| Q4 24 | 39.7% | 61.5% | ||
| Q3 24 | 39.4% | 64.1% | ||
| Q2 24 | 39.9% | 64.9% | ||
| Q1 24 | 39.0% | 61.4% |
营业利润率XMTRZLAB
| Q4 25 | -4.6% | -54.6% | ||
| Q3 25 | -6.1% | -42.3% | ||
| Q2 25 | -6.3% | -50.3% | ||
| Q1 25 | -10.2% | -53.3% | ||
| Q4 24 | -7.8% | -62.6% | ||
| Q3 24 | -8.1% | -66.6% | ||
| Q2 24 | -11.5% | -76.0% | ||
| Q1 24 | -14.6% | -80.7% |
净利率XMTRZLAB
| Q4 25 | -4.5% | — | ||
| Q3 25 | -6.4% | -31.2% | ||
| Q2 25 | -16.3% | -37.3% | ||
| Q1 25 | -10.0% | -45.8% | ||
| Q4 24 | -6.7% | — | ||
| Q3 24 | -7.2% | -40.9% | ||
| Q2 24 | -10.3% | -80.2% | ||
| Q1 24 | -13.5% | -61.4% |
每股收益（稀释后）XMTRZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $219.1M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $275.6M | $715.5M |
| 总资产 | $703.7M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资XMTRZLAB
| Q4 25 | $219.1M | $689.6M | ||
| Q3 25 | $224.5M | $717.2M | ||
| Q2 25 | $225.8M | $732.2M | ||
| Q1 25 | $231.4M | $757.3M | ||
| Q4 24 | $239.8M | $779.7M | ||
| Q3 24 | $234.0M | $616.1M | ||
| Q2 24 | $240.9M | $630.0M | ||
| Q1 24 | $253.8M | $650.8M |
股东权益XMTRZLAB
| Q4 25 | $275.6M | $715.5M | ||
| Q3 25 | $272.0M | $759.9M | ||
| Q2 25 | $270.4M | $791.7M | ||
| Q1 25 | $309.9M | $810.8M | ||
| Q4 24 | $314.5M | $840.9M | ||
| Q3 24 | $315.2M | $667.7M | ||
| Q2 24 | $315.8M | $704.2M | ||
| Q1 24 | $320.4M | $762.2M |
总资产XMTRZLAB
| Q4 25 | $703.7M | $1.2B | ||
| Q3 25 | $698.9M | $1.2B | ||
| Q2 25 | $687.0M | $1.2B | ||
| Q1 25 | $690.1M | $1.2B | ||
| Q4 24 | $680.1M | $1.2B | ||
| Q3 24 | $678.2M | $985.3M | ||
| Q2 24 | $678.6M | $987.4M | ||
| Q1 24 | $692.5M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | -3.0% | -21.0% |
| 资本支出强度资本支出/营收 | 5.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-24.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流XMTRZLAB
| Q4 25 | $4.4M | $-26.0M | ||
| Q3 25 | $5.8M | $-32.0M | ||
| Q2 25 | $-427.0K | $-31.0M | ||
| Q1 25 | $-3.7M | $-61.7M | ||
| Q4 24 | $9.1M | $-55.8M | ||
| Q3 24 | $-3.6M | $-26.8M | ||
| Q2 24 | $-9.1M | $-42.2M | ||
| Q1 24 | $-11.7M | $-90.1M |
自由现金流XMTRZLAB
| Q4 25 | $-5.9M | $-26.7M | ||
| Q3 25 | $-1.7M | $-35.0M | ||
| Q2 25 | $-7.4M | $-33.9M | ||
| Q1 25 | $-9.2M | $-63.2M | ||
| Q4 24 | $4.5M | $-58.4M | ||
| Q3 24 | $-8.4M | $-28.2M | ||
| Q2 24 | $-13.5M | $-42.9M | ||
| Q1 24 | $-16.1M | $-91.1M |
自由现金流率XMTRZLAB
| Q4 25 | -3.0% | -21.0% | ||
| Q3 25 | -0.9% | -30.4% | ||
| Q2 25 | -4.5% | -31.1% | ||
| Q1 25 | -6.1% | -59.9% | ||
| Q4 24 | 3.1% | -53.8% | ||
| Q3 24 | -6.0% | -27.7% | ||
| Q2 24 | -10.2% | -42.9% | ||
| Q1 24 | -13.1% | -104.5% |
资本支出强度XMTRZLAB
| Q4 25 | 5.3% | 0.5% | ||
| Q3 25 | 4.1% | 2.6% | ||
| Q2 25 | 4.3% | 2.6% | ||
| Q1 25 | 3.6% | 1.5% | ||
| Q4 24 | 3.1% | 2.4% | ||
| Q3 24 | 3.4% | 1.3% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 3.5% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
